Eupraxia Pharmaceuticals (EPRX) Accounts Payables (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Accounts Payables data on file, last reported at $7.2 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 233.4% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $7.2 million, a 233.4% increase from a year earlier, with the FY2025 full-year figure at $5.5 million, up 83.06% from the prior year.
• Accounts Payables for Q1 2026 stood at $7.2 million, up from $5.5 million in the prior quarter.
• Over the last five years, Accounts Payables for EPRX reached as high as $7.2 million in Q1 2026 and fell as low as $2.0 million in Q2 2024.
• Historically, Accounts Payables has averaged $3.6 million across 5 years, with a median of $3.0 million in 2024.
• Across the five-year window, Accounts Payables slumped 45.94% in 2025 and surged 233.4% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $2.9 million in 2022, then surged by 33.92% to $3.9 million in 2023, then declined by 22.7% to $3.0 million in 2024, then jumped by 83.06% to $5.5 million in 2025, then increased by 29.0% to $7.2 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $7.2 million in Q1 2026, $5.5 million in Q4 2025, and $3.7 million in Q3 2025.